MedTrace Logo

Prevalence and Risk Factors of Chronic Thrombo-embolic Disease After a Pulmonary Embolism Event

NCT05073666 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 123

Last updated 2025-03-06

No results posted yet for this study

Summary

Venous thromboembolic disease (VTE) is a common clinical entity whose two manifestations are deep vein thrombosis (DVT) and pulmonary embolism (PE). After an acute PE, almost half of the patients complain residual dyspnea, despite well-conducted curative anticoagulation. Some will present persistent defects on lung scan-scintigraphy, without pulmonary hypertension. This condition defines Chronic-Thrombo-Embolic Disease(CTED). The prevalence of CTED after PE is poorly known as are its risk factors.

The primary objective is to determine the prevalence of CTED at 3 or 6 months, depending on the provoked or unprovoked character, after a PE.

The secondary objectives are:

* To determine the potential risk factors for the occurrence of CTED.
* To look for an association between the persistence of DVT and the occurrence of CTED.
* To look for an association between the diagnosis of CTED and PE recurrence during the 12-month follow-up.
* To determine the diagnostic performance of the clinician alone compared to the lung scintigraphy (gold standard) for the diagnosis of CTED.
* To compare the impact on the quality of life (QoL) with or without CTED.
* To determine the correlation between impaired QoL and the degree of residual obstruction on lung scintigraphy.

Conditions

  • Chronic Emboilism

Interventions

OTHER

NO INTERVENTION

NO INTERVENTION

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Nice

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2023-02-03
Completion
2023-02-03

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05073666 on ClinicalTrials.gov